Abstract:BACKGROUND: Cancer cells selectively promote the translation of oncogenic transcripts to stimulate cancer progression. Although growing evidence has revealed that tRNA modifications and related genes participate in this process, their roles in head and neck squamous cell carcinoma (HNSCC) remain largely uncharacterized. Here, we sought to investigate the function and mechanisms of the transfer RNA (tRNA) N7-methylguanosine (m7 G) modification in regulating the occurrence and development of HNSCC.METHODS: Cell lost-of-function and gain-of-function assays, xenograft models, conditional knockout and knockin mouse models were used to study the physiological functions of tRNA m7 G modification in HNSCC tumorigenesis. tRNA modification and expression profiling, mRNA translation profiling and rescue assays were performed to uncover the underlying molecular mechanisms. Single-cell RNA sequencing (scRNA-seq) was conducted to explore the tumor microenvironment changes.RESULTS: The tRNA m7 G methyltransferase complex components Methyltransferase-like 1 (METTL1)/WD repeat domain 4 (WDR4) were upregulated in HNSCC and associated with a poor prognosis. Functionally, METTL1/WDR4 promoted HNSCC progression and metastasis in cell-based and transgenic mouse models. Mechanistically, ablation of METTL1 reduced the m7 G levels of 16 tRNAs, inhibiting the translation of a subset of oncogenic transcripts, including genes related to the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway. In addition, chemical modulators of the PI3K/Akt/mTOR signaling pathway reversed the effects of Mettl1 in mouse HNSCC. Furthermore, scRNA-seq results revealed that Mettl1 knockout in mouse tumor cells altered the immune landscape and cell-cell interaction between the tumor and stromal compartment.CONCLUSIONS: The tRNA m7 G methyltransferase METTL1 was found to promote the development and malignancy of HNSCC through regulating global mRNA translation, including the PI3K/AKT/mTOR signaling pathway, and found to alter immune landscape. METTL1 could be a promising treatment target for HNSCC patients.

N7-Methylguanosine Trna Modification Enhances Oncogenic Mrna Translation and Promotes Intrahepatic Cholangiocarcinoma Progression

METTL5-mediated 18S Rrna M6a Modification Promotes Oncogenic Mrna Translation and Intrahepatic Cholangiocarcinoma Progression.

METTL1 Promotes Hepatocarcinogenesis Via M7g Trna Modification‐dependent Translation Control

METTL1 promotes hepatocarcinogenesis via m7 G tRNA modification-dependent translation control

Aberrant translation regulated by METTL1/WDR4‐mediated tRNA N7‐methylguanosine modification drives head and neck squamous cell carcinoma progression

N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression

WDR4 promotes HCC pathogenesis through N7-methylguanosine by regulating and interacting with METTL1

Aberrant Translation Regulated by METTL1/WDR4-Mediated Trna N 7-Methylguanosine Modification Drives DLBCL Progression

Targeting N7-methylguanosine Trna Modification Blocks Hepatocellular Carcinoma Metastasis after Insufficient Radiofrequency Ablation

N7-methylguanosine (m7G) tRNA modification: a novel autophagy modulator in cancer

N7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma

METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation

Exploring the role of m7G modification in Cancer: Mechanisms, regulatory proteins, and biomarker potential

Integrative Pan-Cancer Analysis and Clinical Characterization of the N7-methylguanosine (m7g) RNA Modification Regulators in Human Cancers

N7-methylguanosine modification: from regulatory roles to therapeutic implications in cancer

N6-methyladenosine modification in 18S rRNA promotes tumorigenesis and chemoresistance via HSF4b/HSP90B1/mutant p53 axis

N7-methylguanosine Regulatory Genes Well Represented by METTL1 Define Vastly Different Prognostic, Immune and Therapy Landscapes in Adrenocortical Carcinoma.

N6-methyladenosine (m6a) in 18S Rrna Promotes Fatty Acid Metabolism and Oncogenic Transformation.

Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy